Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mountain View Pharmaceuticals Inc.

www.mvpharm.com

Latest From Mountain View Pharmaceuticals Inc.

US Capitol Capsule: Rare Diseases: The Path To Precision Medicine

The path to achieving the promise of precision medicine – prevention and treatment strategies that take individual variability in genes, environment and lifestyle into account – must go through the discovery, research and development processes of rare diseases, a panel of experts and advocates said last week during a Capitol Hill briefing hosted by the House Rare Disease Congressional Caucus, headed by Reps. Leonard Lance (R-NJ) and Joe Crowley (D-NY).

Immune Disorders Cancer

Novo's Saxenda bags FDA approval for weight management

With US FDA approval for Saxenda (liraglutide) Novo Nordisk could be a contender in the market for prescription weight loss drugs, which so far has yielded disappointing sales from oral obesity therapies approved in the US since 2012 starting with Belviq (lorcaserin) from Arena Pharmaceuticals.

Gastrointestinal Metabolic Disorders

23andMe's genome test launches in UK after US ban

23andMe, a genetic testing firm which entered a partnership in September with Pfizer to push the idea of personalized medicines (scripintelligence.com, 1 September 2014), has launched its Personal Genome Service in the UK – a program that has been banned in the US.

Orthopedics Respiratory

INTERVIEW: 23andMe uses people power to push personalized medicine into new fields

23andMe's announcement earlier this month that it had teamed up with Pfizer in inflammatory bowel disease (IBD) could pave the way for the expansion of personalized medicine into a new area.

Gastrointestinal Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mountain View Pharmaceuticals Inc.
  • Senior Management
  • John A French, CFO
    Merry R Sherman, PhD, Pres.
    L. D Williams, PhD, VP, R&D
    Mark G Saifer, PhD, VP, Bus. Dev.
  • Contact Info
  • Mountain View Pharmaceuticals Inc.
    Phone: (650) 365-5515
    3475-S Edison Way
    Menlo Park, CA 94025-1821
    USA
UsernamePublicRestriction

Register